The Pharma Data

JANUARY 6, 2021

The complete text of the article titled, “Neuronal Delivery of Antibodies has Therapeutic Effects in Animal Models of Botulism,” can be found h e re. Following in vitro validation of therapeutic mechanisms, efficacy studies were conducted in mice, guinea pigs and rhesus macaque monkeys.

Medicine 52

Medicine Antibody Protein In-Vitro 52

The Pharma Data

DECEMBER 2, 2020

Progenity provides in vitro molecular tests designed to improve lives by providing actionable information that helps guide patients and physicians in making medical decisions during key life stages. SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. About Progenity. Progenity, Inc. Progenity, Inc.

In-Vitro 40

In-Vitro Sales Containment Development 40

The Pharma Data

MAY 15, 2023

Food and Drug Administration (FDA) has accepted the company’s supplemental Biologics License Application (sBLA) for Vabysmo® (faricimab) for the treatment of macular edema following retinal vein occlusion (RVO). 1,2 Vabysmo’s safety profile was consistent with previous trials. In BALATON, vision gains were +16.9

Antibody 40

Antibody In-Vitro Clinical Development Medicine 40

The Pharma Data

DECEMBER 2, 2020

SAN DIEGO, Dec. 02, 2020 (GLOBE NEWSWIRE) — Progenity, Inc. NASDAQ: PROG) today announced the pricing of its offering of $75.0 The issuance and sale of the notes are scheduled to settle on December 7, 2020, subject to customary closing conditions. million principal amount of notes. per share of common stock.

Sales 40

Sales In-Vitro Containment Development 40

XTalks

OCTOBER 1, 2020

Xtalks spoke with WeiQi Lin, MD, PhD, executive vice president, research & development, and principal scientist at DURECT Corporation — a company focused on developing drugs and drug delivery methods in therapeutic areas with significant unmet need — about her transition from academia to industry. Key Moments.

Scientist 52

Scientist In-Vitro Research Life Science 52

The Pharma Data

APRIL 12, 2023

The abstracts showcase the strength and breadth of Roche’s Ophthalmology portfolio, including post-hoc data from phase III Vabysmo® (faricimab) studies that support its benefit in drying retinal fluid in neovascular or ‘wet’ age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Antibody 40

Antibody In-Vitro Development Trials 40

Roots Analysis

OCTOBER 22, 2023

In the last few years, researchers have become interested in using in vitro transcribed (IVT) mRNA as a drug delivery agent. Furthermore, these drug candidates can be used to develop precise and individualized therapies that allow patients to produce therapeutic proteins in their own bodies.

RNA 40

RNA Protein Genetics Gene Expression 40

pharmaphorum

DECEMBER 15, 2022

Oxsonics Therapeutics, which offers an ultrasound-based drug delivery platform, appointed Jérôme Marzinski, a board member at Cimon Medical and former CEO of ophthalmic diagnostic company Visiometrics into its top job. The month of November saw a number of notable hires and personnel moves in biotech and pharma. More CEO shakeups.

Sales 52

Sales In-Vitro Antibody Drug Delivery 52

The Pharma Data

JANUARY 16, 2021

It has become the de facto standard equipment for high titer transient protein expression platforms used by many leading Chinese antibody drug pharmaceutical companies and IVD (In Vitro Diagnostics) companies since its launch in Oct. for non-viral cell immunotherapeutic drug development. JS Bio’s parent company.

Protein 52

Protein Production Antibody In-Vitro 52